Tag: ETST

420 with CNW – Lithuania Joins List of EU Nations Where Medical Cannabis is Legal

The parliament of Lithuania has passed a law that will make it possible for patients who want to be treated with marijuana to get such treatment. This new law will become operational on May 1, 2019. An overwhelming majority (nearly unanimous) of legislators voted in for this law. No legislator voted against the proposal while one lawmaker abstained.

Any company intending to sell medical cannabis once the new law takes effect will need to get a license from the relevant regulator in the country.

The passing of the law which legalized medical cannabis necessitated that some existing laws, such as the law on Narcotics and Psychotropic Substances, be amended to take into account the legalization of medical marijuana.

One of the provisions of the narcotics law regarded marijuana as having no medicinal use. Such a provision would have been inconsistent with the new law which regarded cannabis as a form of medicine.

The law legalizing medical cannabis has some strict requirements for any cannabis product that manufacturers want to use to treat patients. For example, scientific research will have to be conducted to prove that a given product has a medicinal effect upon the condition for which such a product can be used.

The medicines control agency of the country will be responsible for issuing permits for any clinical trials that need to be conducted.

Aurora Cannabis, one of the leading marijuana companies in Canada, already has a presence in the country. This was after the Canadian company acquired Agropro UAB in September this year.

Agropro had for long occupied the position of the largest firm involved in the production, processing and supply of organic hemp products in Europe.

Registered cannabis products will be used to treat oncological patients in Lithuania. Qualifying conditions will include HIV/AIDS, multiple sclerosis, severe epilepsy and other chronic conditions.

Other EU jurisdictions which have recently legalized medical cannabis include the UK which passed the relevant law and implementation is scheduled to start just weeks after that law was passed. This is contrary to what happens in other jurisdictions where several months or even years have to elapse before implementation starts. The delays are usually necessitated by the need to set up regulatory systems and process applications for businesses that want to be involved in the industry.

Lithuania is taking it slow and giving itself more than half a year before patients can access medical marijuana. Cannabis companies around the world, such as Earth Science Tech, Inc. (OTCQB: ETST) and FinCanna Capital Corp. (CSE: CALI) (OTCQB: FNNZF) are certainly happy that more jurisdictions around the world are opening up to the medical benefits that cannabis can offer those in need.

More from CannabisNewsWire

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

420 with CNW – Alaska Decides to Modify Marijuana Taxes

The state of Alaska has decided to make some changes to the way it taxes marijuana. These changes were prompted by concerns raised by industry players regarding the lack of distinction between different kinds of cannabis buds.

The type of bud plays a role in the quality (and the price) of any products that are derived from that bud. The tax authorities haven’t been putting this into consideration, an oversight that made legal cannabis very pricey hence inadvertently promoting the black market.

Currently, each ounce of cannabis flower or bud is taxed $50 while trim (the rest of the plant) incurs a $15 tax per ounce. These taxes are paid by the grower as the produce is sent to a manufacturing facility or to a retail store where it is sold as dry bud or any other unprocessed form of the plant.

The new tax measures which will start being implemented on January 1, 2019 will see mature flower or bud incur an excise tax of $50 an ounce while the abnormal or immature flower will attract a $25 tax for each ounce. The rest of the plant will still be taxed at the same level as before, which is, $15 an ounce.

The planned tax changes will see three tiers of taxes for different kinds of marijuana. Many industry participants see these changes as insufficient and they are calling for wide ranging modifications.

However, those broader changes can only be made by the legislative arm of the state by modifying the law under which cannabis became legal in Alaska.

Conducting such extensive reforms would be a time-consuming process that would involve numerous steps, such as conducting hearings in order to gather views from the public and other stakeholders before the appropriate committee prepares a report to be voted on by all legislators.

Alaskans voted in 2014 to decriminalize recreational marijuana and that ballot measure took effect towards the end of February the following year.

Supply shortages compelled many marijuana retailers to close shop for a while in December 2016 and the first month of 2017. These businesses reopened once the shortages were fixed.

The existing tax policy was threatening to take some marijuana companies out of business and the limited changes being made are attempts to allow businesses to lock in some profits so that the industry can remain robust. Earth Science Tech, Inc. (OTCQB: ETST) and FinCanna Capital Corp. (CSE: CALI) (OTCQB: FNNZF) can only hope that all jurisdictions move to make the business environment more favorable to the players.

More from CannabisNewsWire

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

420 with CNW – Connecticut Federal Court Rules in Favor of Employees Taking Medical Marijuana

A federal district court has ruled that a nursing home violated the anti-discriminatory act when it rescinded a job offer to a job seeker who declared that she consumes medical cannabis off-duty and tested positive for THC in a pre-employment drugs test. Medical cannabis is legal in Connecticut where the plaintiff lives and sought to be employed by the nursing home.

The case was filed by the plaintiff last year and judgment was delivered last month, more than a year later. The defendant had tried to get the case dismissed arguing that federal laws allowed them to deny users of a controlled substance employment.

However, the federal district court ruled that the defendant couldn’t cite the Controlled Substances Act since the laws of Connecticut granted protections to patients who had a qualifying condition and were consuming marijuana in accordance with the state laws.

The plaintiff’s request for legal fees and punitive damages was denied by the federal court since the Connecticut law (Palliative Use of Medical Marijuana or PUMA) under which she sued did not prescribe such remedies in its protections for patients on medical cannabis.

The ruling against Bride Brook Nursing and Rehabilitation Center comes at a time when courts had initially ruled against employees on matters of medical marijuana. It is the first time that a federal court is making a decision in favor of an employee.

Other state courts had made similar favorable rulings for employees against employers who took action against them for consuming medical marijuana.

The decision by the federal court isn’t binding on all the other courts, but one can be certain that this case will be a point of reference in any future litigation on similar matters.

In fact, Bride Brook Nursing and Rehabilitation Center can appeal against this decision in order to have it reversed.

The case law on medical marijuana is still scanty since so few states have decriminalized it while it remains illegal at the federal law.

It may therefore be premature for anyone to think that the legal tide is shifting in favor of employees. All the same, it is wise for employers to review their policies regarding marijuana testing as a precondition for employment since they may expose themselves to costly suits that may leave the reputation of the companies in question in tatters.

What can help all concerned is some form of middle ground to be reached between the states where marijuana is legal and the federal level where decriminalization hasn’t occurred as yet. This is certainly the wish of industry players like Earth Science Tech, Inc. (OTCQB: ETST) and FinCanna Capital Corp. (CSE: CALI) (OTCQB: FNNZF) who want to see a more uniform regulatory framework.

More from CannabisNewsWire

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

420 with CNW – South African Court Declares Personal Use of Cannabis Legal

The constitutional court of the Republic of South Africa made a pivotal ruling last week making it legal for adults to grow, possess and consume cannabis in private.

This case reached the constitutional court after a regional court in Western Province (the province in which the Federal capital of the country is found) ruled that the law banning the use of dagga (the local term for marijuana) by adults in private was unconstitutional.

The government appealed that decision before the highest court on the matter, and Deputy Chief Justice Zondo delivered the binding ruling in favor of the decriminalization of private personal growth, possession and use of marijuana. This reaffirmed the decision of the lower court.

The government is now left with no other option than to implement the ruling.

Indeed, the court gave the legislative arm of the government 24 months within which to come up with an enabling law that will actualize the constitutional court’s ruling.

For example, that law will define how much cannabis someone can have for personal use. The number of plants that an adult can grow for his or her personal, private use will also be clarified once the requisite law is passed by parliament.

In the meantime, cannabis users can point to the court’s ruling as their protection while found cultivating, using or in possession of cannabis in private. Any public possession or consumption of marijuana remains illegal.

It should be noted that various sections of the government, such as the health department and law enforcement, opposed cannabis decriminalization, saying that it posed health risks and could pave the way for people to graduate to stronger substances/illicit drugs. The court has rendered those arguments moot.

South Africa becomes the third country in Africa to permit some form of cannabis use. Lesotho took the honor of being the first country on the continent to legalize medical cannabis last year. Zimbabwe followed suit this year in April. Globally, Uruguay took the lead in legalizing cannabis in 2013.

This small number of African countries in which marijuana is legal in some way is baffling given that approximately 10,000 metric tons of cannabis are cultivated on the continent each year.

The picture is no different across the world ,with possession or consumption of cannabis attracting the death penalty in Saudi Arabia, while Canada is just days away from starting the retail sale of recreational cannabis after allowing the medical use of marijuana years back.

Are the winds of change blowing firmly in favor of the cannabis industry across the world? Choom Holdings Inc. (CSE: CHOO) (OTCQB: CHOOF) and Earth Science Tech, Inc. (OTCQB: ETST) must be hoping that the legal hurdles to the availability of medical cannabis are removed so that the public can reap the benefits that this often controversial plant has to offer.

More from CannabisNewsWire

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

420 with CNW – EU Parliament Drafts Medical Marijuana Law

Currently, each EU member country is responsible for formulating and implementing its own cannabis laws as it sees fit. This has created a lot of contradictions and inconsistencies between the laws of the member states. This situation is bound to change in the event that the draft law that is being worked on by the health committee passes through all the stages and is endorsed by the EU council of ministers.

A public hearing is planned for October 1 to discuss the feasibility of that proposal.

One of the key aims of the draft law is to state how medical cannabis differs from any other uses to which marijuana can be put, especially the recreational use of the substance.

The bill will also ensure that all who need medical cannabis can access it. For example, medical marijuana should be covered by insurance providers in the EU in the same way that other forms of medicine are covered.

The draft also seeks to speed up research on the various medicinal uses of marijuana so that accurate information can be availed to the public. Such research could also uncover previously unknown medicinal uses of cannabis and help patients who would have otherwise lost all hope of seeing any improvement in their conditions.

EU member states would also be required to reform their existing cannabis laws in order to allow medical professionals/doctors and pharmacists to prescribe and avail medicinal marijuana without any legal roadblocks to the execution of their professional duties.

The law is intended to curb the black market of medical cannabis by controlling the points at which medical cannabis is sold. Such controls can have the added benefit of limiting underage access to the products.

The process of getting this draft law through all the stages until it is endorsed by the council of EU ministers is lengthy. It is estimated that it may take about eight months for the draft to reach the endorsement stage.

More sobering, however, is the fact that a resolution of the EU parliament doesn’t have any legal force in the member countries. At best, it can only be looked at as a recommendation which may or may not be implemented.

The brighter side of such proposals/resolutions is that they can serve as fodder for advocacy groups to pressure national governments to reform their prohibitionist laws in order to align the countries with the position taken at EU level. Proponents of cannabis decriminalization can therefore take pride in the fact that the EU is waking up to the medicinal roles that cannabis can play in the lives of citizens.

Entities like PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) and Earth Science Tech, Inc. (OTCQB: ETST) can only wish that the proposed harmonization of cannabis laws in the EU happens across the globe so that they don’t have the headache of dealing with different cannabis legal regimes in each jurisdiction where these companies operate.

More from CannabisNewsWire

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

420 with CNW – Drama Characterizes Passing of Cannabis Bill by Congressional Committee

The Medical Cannabis Research Act was finally passed by the House Judiciary Committee of Congress. This was the first time in 50 years that a Republican-dominated congressional committee has passed any legal cannabis reform legislation.

Republic Mathew Gaetz and 40 other cosponsors set the momentum rolling for the Thursday vote, which paved the way for additional facilities to get licenses to grow research-grade cannabis.

Congressman Matt Gaetz said that the U.S. had for too long been trapped in a catch-22 situation in which cannabis laws couldn’t be revised due to the absence of sufficient scientific research, yet that needed research could not be conducted due to the existing legal restrictions. Gaetz said that this “logjam” would be untangled by the Act.

Committee chair Bob Goodlatte echoed similar sentiments in his statement on the matter. He said that, while differing opinions exist on the subject of marijuana, there was agreement that scientific information/research was needed to guide the debate.

The statement by Bob Goodlatte could explain why he changed from his opposition to approving any law legalizing any form of cannabis to supporting this Act, which will allow researchers to study the possible medical value of the substance.

The committee sitting did have its share of controversy, however.

Serious objections were mounted to clauses that barred anyone with a drugs-related conviction, whether a misdemeanor or felony conviction, from participating in the legal cannabis industry.

Human Rights Watch, the Drug Policy Alliance and other advocacy groups read statements denouncing those clauses that exclude citizens who have already served punishments for their infractions.

Their view is that ex-convicts should be helped to get employment rather than be hindered from becoming productive members of their communities.

Gaetz shocked committee members when he confessed that the language in question wasn’t in his original draft of the bill. However, he was prevailed upon by cannabis industry firms to include that wording in order to keep “riff-raff” from applying for a cannabis research or cultivation license! Companies like Earth Science Tech, Inc. (OTCQB: ETST) and Pacific Software, Inc. (OTC: PFSF) would certainly not be party to such an action since they believe in free and ethical enterprise.

Committee chairman Goodlatte promised to find a way to address the concerns about that “unacceptable” language/clause before the Act is forwarded to the entire house for a vote.

It is widely believed that the Senate will be an easier ground for the Act to navigate and obtain approval.

What is now left is to wait for the Act to be scheduled on the business of Congress. When will that happen? Your guess is as good as ours.

More from CannabisNewsWire

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

The CBD Bonanza on the Horizon

CannabisNewsWire Editorial Coverage: Leveraging ever-expanding scientific evidence of the therapeutic efficacy of CBD (cannabidiol), specialty biotechnology companies are creating novel new formulations of the chemical compound to capitalize on the titanic growth expected in the cannabis-derived pharmaceutical and nutraceutical markets.

Cannabinoids have been used for medicinal purposes for millennia, but it wasn’t until the discovery of the human endocannabinoid system in the 1990s that scientists began to comprehend their importance in healing and homeostasis. The identification of human cannabinoid receptors opened the floodgates to new cannabis-based medications. Increased understanding of the endocannabinoid system sparked further scientific research and led to the realization that cannabinoids impact a much wider range of physiological functions than previously realized. Specialty biotechnology companies soon blossomed and now these companies research and develop wide-ranging novel new drug candidates to improve and extend patients’ lives, creating unique medicines to treat multiple maladies and answer unmet medical needs. These pioneering biotech companies are committed to developing cannabis-based pharmaceuticals and nutraceuticals delivered with unparalleled safety and new-found efficacy. At the vanguard of this surge in cannabinoid therapeutics, Earth Science Tech, Inc. (OTC: ETST) (ETST Profile) has taken another major step in its mission to become a global leader in the research, development and sale of hemp-derived, CBD–based pharmaceuticals, nutraceuticals and dietary supplements. The company’s recent decision to uplist on the OTCQB exchange will likely increase visibility and liquidity, and its comprehensive strategy of scientific development combined with robust retail creates a unique opportunity in the burgeoning medical cannabis markets. Other companies vying for position in these lucrative markets include CV Sciences, Inc. (OTC: CVSI), Axim Biotechnologies, Inc. (OTC: AXIM), GB Sciences, Inc. (OTC: GBLX) and Vitality Biopharma (OTC: VBIO).

To view an infographic of this editorial, click here.

Massive Markets

Little wonder that cannabis biotech companies are operating at full throttle. The global medical marijuana market is anticipated to exceed $55 billion by 2025 and, to meet increasing consumer demand, hemp-based nutraceuticals are rapidly gaining significant traction in a global nutraceuticals market projected to surpass $319 billion within the next five years. These eye-popping projections bode well for diversified cannabis biotech companies. CBD pharmaceuticals and nutraceuticals are the fastest growing sectors in the legal cannabis markets and the sector itself is among the fastest growing in all the markets. With multiple clinical research studies suggesting that CBD based pharmaceuticals and nutraceuticals have the potential to treat arthritis, MS, chronic pain, depression, epilepsy and a myriad of other illnesses and maladies, the prodigious market projections might even be underestimated.

Another Milestone

Seizing on the immense market opportunity and validating efficacy through scientific processes, Earth Science Tech, Inc. (OTC: ETST) is intent on becoming a global leader in the research, development and sale of hemp-derived, CBD-based pharmaceuticals, nutraceuticals and dietary supplements.  The company has racked up a succession of achievements since inception and its latest announcement establishes another milestone in its march toward global recognition. The company just issued a press release confirming that the U.S. Securities and Exchange Commission (SEC) approved the company’s Form 10 Registration Statement and Earth Sciences has officially up-listed to an OTCQB fully reporting company as of Sept. 10. The higher standards of the OTCQB markets provide a strong baseline for transparency, as well as the technology and regulations to enhance both access to information and trading experiences for investors. “Historically, up-listing to the OTCQB and being fully reporting has resulted in greater liquidity and awareness. We are committed to the higher level of corporate and financial disclosures required as an OTCQB fully reporting company, demonstrating our commitment to our loyal shareholders,” stated ETST’s President, Director and Chairman Nickolas S. Tabraue.

Eyes on the Prize

Grounded in science, ETST still understands that sales are essential for continued success. Earth Science aggressively markets and sells the highest-available quality and purity full spectrum hemp oil containing CBD. The company’s products are formulated using superior supercritical CO2 cold liquid extraction, where the cannabinoids are kept at the rawest state possible to maintain essential therapeutic properties. Earth Science’s CBD products are marketed through multiple venues including a national group of independent distributors representing grocery and convenience stores, a national association of buying groups and trade organizations reaching up to 90,000 retail outlets, health food giant Karmavore Superfoods, international supplement distributor Forzagen, innumerable vape and e-liquid smoke shops, and online.

The company has four distinct, wholly owned subsidiaries:

  • Cannabis Therapeutics, Inc., (CTI) is developing an array of cannabinoid-based pharmaceuticals and nutraceuticals.
  • Kannabidioid, Inc., manufactures and distributes vapes/e-liquids and gummy edibles to vape and smoke shops.
  • Earth Science Pharmaceutical, Inc., (ESP) manufactures low-cost medical devices and vaccines for protection against sexually-transmitted infections.
  • Earth Science Foundation, Inc., a nonprofit organization formed to accept grants and donations to conduct further studies and help donate CBD products to those in need.

Cannabis Therapeutics is deeply invested in research and development to explore and harness the medicinal power of cannabidiol. Over 113 cannabinoids have been isolated from the cannabis plant, many obscure and only in trace amounts, but CBD, for which Cannabis Therapeutics has a provisional application patent, is the most promising of all. CTI’s mission is to develop proprietary cannabinoid-based nutraceuticals and pharmaceutical products using Earth Science Tech’s existing cannabis CBD patent and IP, as well as expected future technologies.

The company recently updated its report on research progress on two new cannabinoid-based pharmaceutical drugs, which are unique CBD formulated products – a neuron protector and a breast protector. Earlier studies by DV Biologics, a leading biological company, confirmed ETST high-grade hemp CBD oil deterred the formation of reactive oxygen species and cell death in human brain cells in vitro and may serve as a neuroprotectant to mitigate neurodegenerative disorders such as Alzheimer’s and Parkinson’s. With strong initial evidence that CBD contains anti-breast cancer properties, Earth Sciences also launched the development of proprietary prophylactic therapies to prevent breast cancer, and a treatment to help women with aggressive breast cancer. The company is very bullish on these CBD formulas.

The R&D work in progress at the prestigious laboratory, Centre De Développement Bioalimentaire Du Québec (CDBQ), has been exceptionally promising. CDBQ is highly experienced and able to utilize the most effective and economical solutions to develop products with the best efficacy and price-to-quality-to-market ratios. CDBQ is meticulously finalizing formulations that will include natural protective agents to assure long shelf life of the CBD formula.

The third CBD formula is a revolutionary superfood with unique organoleptic properties never seen on the market. Formulated from a mix of hemp oil and other vegetal oils, and enriched with a highly potent antioxidant, this product is designed to improve antioxidant ingestion. Earth Science developed this novel formula in collaboration with experts that successfully developed multiple products for some of the largest players in the food industry.

Not a One-trick Pony

Earth Science’s up-listing announcement is only the latest in a succession of successful advancements the company has made since its genesis. Last year’s achievements verify that.  In addition to talented and experienced leadership, the company’s success lies in the broad diversification of products, joint ventures, IPs and initiatives. Beyond the company’s multiple CBD-based initiatives and ventures, Earth Science’s medical device subsidiary Earth Science Pharmaceutical is making significant strides in the development of low-cost, noninvasive diagnostic tools, medical devices, testing processes and vaccines for sexually transmitted infections and/or diseases. The company’s first medical device, MSN-2, is a home kit designed for the detection of STIs, such as chlamydia, from a self-obtained gynecological specimen. ESP is working to develop and bring to market medical devices and vaccines that meet the specific needs of women.

Others Vying for Position

CV Sciences, Inc. (OTC: CVSI) focuses on the drug development, marketing and sale of products containing cannabidiol as the active pharmaceutical ingredient, and is engaged in the sale of CBD as well. The company operates two distinct business segments: a drug development division focused on developing and commercializing novel therapeutics utilizing synthetic CBD; and a consumer product division centered in the manufacturing, marketing and sale of plant-based CBD products to a range of market sectors.

Axim Biotechnologies, Inc. (OTC: AXIM) researches, develops and produces cannabis-based pharmaceutical, nutraceutical and cosmetic products. The company has several products developed or in developmental stage for the treatment and/or prevention of multiple conditions and symptoms. Axim’s flagship products include a CBD-based, controlled-release chewing gum, another gum containing 50 mg of CBD undergoing clinical trials in patients with irritable bowel syndrome, and a combination CBD/tetrahydrocannabinol (THC) gum that will undergo clinical trials for the treatment of pain and spasticity associated with MS.

GB Sciences, Inc. (OTC: GBLX) is a diverse cannabis company focused on standardized cultivation and production methods, as well as biopharmaceutical research and development. The company’s goal is to create safe, standardized, pharmaceutical-grade cannabinoid therapies that target a variety of medical conditions. Company growth strategy is two-pronged — biomedical research for the development of cannabis-based therapies and the recreational market for cannabis in Nevada.

Vitality Biopharma (OTC: VBIO) is focused on the use of cannabinoids for the treatment of serious neurological and inflammatory disorders. The company has developed cannabinoid prodrugs, known as cannabosides, which upon ingestion may enable selective delivery of THC and CBD to the gastrointestinal tract. Vitality has filed intellectual property applications and is seeking global patent protection for prodrugs of THC, CB, and CBDV, as well as for its proprietary prodrug biosynthesis platform utilizing enzymatic glycosylation.

The Takeaway

As the list of curative applications continues to grow, there’s no longer any doubt about the therapeutic efficacy of cannabidiol. Employing that same certitude for impending CBD market growth has the potential to create a profit bonanza in strategically positioned portfolios.

For more information on Earth Science Tech, visit Earth Science Tech, Inc. (OTC: ETST)

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

Receive Text Alerts from CannabisNewsWire: Text “Cannabis” to 21000

For more information please visit https://www.CannabisNewsWire.com and or https://CannabisNewsWire.News

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

DISCLAIMER: CannabisNewsWire (CNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by CNW are solely those of CNW. Readers of this Article and content agree that they cannot and will not seek to hold liable CNW for any investment decisions by their readers or subscribers. CNW is a news dissemination and financial marketing solutions provider and is NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, CNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.

CNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and CNW undertakes no obligation to update such statements.

Earth Science Tech, Inc. (ETST): Transparency, Scientific Research and Future Products

  • Received grant from Government of Québec through Canno Inno Laboratories subsidiary
  • Canna Inno Laboratories enhances collaboration between the company’s resources in Canada and the U.S. while providing access to grants
  • Sound scientific research and transparent studies

Earth Science Tech, Inc. (OTC: ETST), a Florida-based biotechnology company focused on cannabis, industrial hemp and cannabinoid research and development for nutraceuticals, pharmaceuticals and medical devices, announced last week that its subsidiary, Canna Inno Laboratories Inc., has received a grant from the Government of Québec for innovation in the pharmaceutical industry. ETST plans to apply for additional funding under Canada’s Scientific Research and Experimental Development Tax Credit program (http://cnw.fm/Q2v2O).

Earth Science Tech formed Canna Inno Laboratories, Inc. in 2017. Strategically headquartered in Montreal, Quebec, it allows Earth Science Tech access to Canadian government and private grants offered to companies for innovation in the pharmaceutical industry. The awarded grant will support the pre-launch process of Earth Science’s three CBD-based products. These nutraceutical products aim to prevent common causes of cancer and help reduce occurrence rates. The pre-launch process includes a series of pre-clinical in vitro trials to fight breast cancer and neurodegenerative disorders. Once complete and patent pending, these high-grade hemp CBD oil products will be commercialized as nutraceuticals and provide alternative natural treatment solutions.

Through the in vitro study with the University of Central Oklahoma and DV Biologics, ETST has provided results that confirm the positive effect of its CBD on breast cancer, immune cell function and human brain cells. The goal of ETST is to discover solutions for conditions that currently have no effective treatment, targeting diseases in which the benefits of CBD have already been demonstrated by researchers worldwide. ETST seeks to increase the effectiveness of cannabinoids and/or CBD and thereby improve treatments for different diseases. The company focuses on providing sound scientific research and transparency on the progression of studies done on its highest quality and purity, full spectrum high-grade hemp CBD products.

For more information, visit the company’s website at www.EarthScienceTech.com

More from CannabisNewsWire

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

Earth Science Tech, Inc. (ETST) Enlarges Its Footprint in Hemp-Based CBD Market

  • Agreement with Mr. Checkout will significantly strengthen the company’s product distribution network
  • Human trials launched evaluating CBD-based therapy for opioid addiction
  • Application made to uplist to OTCQB in early 2018, attracting more investment

The worldwide cannabidiol (CBD) oil market, which includes products derived from both marijuana and hemp, is projected to grow at a CAGR of more than 39 percent through 2021. The health benefits of CBD oil are the major driver for growth in this market, with global demand steadily on the rise in recent years. Hemp-based CBD oil products in particular are more popular, as they have a lower concentration of psychoactive compound tetrahydrocannabinol (THC) than those derived from marijuana, therefore not requiring a medical prescription (http://cnw.fm/kaL9i). Earth Science Tech, Inc. (OTC: ETST) is one of the companies that is focused on the development of hemp-based CBD products and has taken a number of steps recently to enlarge its presence in this market sector.

Following a revamp of its CBD product line, Earth Science Tech announced on February 13, 2018, that it had concluded an agreement with Mr. Checkout for the distribution of its products via major retailers and stores across the United States. This agreement will strengthen the company’s distribution network, which currently has 10 active representatives targeting distribution to health food stores and clinics. Mr. Checkout is a national group of independent distributors of products to over 60 major retailers and 55,000 stores. It will market ETST’s product line to major retailers such as Walmart, Walgreens and Target.

Earth Science Tech is a biotechnology company focused on the research and development of hemp-based CBD products for the pharmaceutical and nutraceutical industries. It also has a focus on the development of diagnostic tools and medical devices. On February 28, 2018, the company announced that it had finalized plans to conduct human trials on its new CBD-based formulation that targets opioid addiction (http://cnw.fm/rNnQ0). These trials will assess the efficacy of the combination of hemp-based CBD oil with an essential mineral element. Currently, the sole therapy for this condition is a monotherapy based on an essential mineral element. ETST’s formulation is expected to increase the potency and improve the outcome of this therapy.

The company operates through three wholly owned subsidiaries:

  • Cannabis Therapeutics, Inc. which develops leading edge, cannabinoid-based products for the pharmaceutical and nutraceutical sectors;
  • KannaBidioiD which is focused more on developing products for the recreational use of cannabis, including edibles, vapes and eLiquids;
  • Earth Science Pharma, Inc., which develops medical devices and low-cost, noninvasive diagnostic tools, as well as testing processes and vaccines for sexually transmitted diseases.

Cannabis Therapeutics is in the development stage of two CBD-based pharmaceutical drugs and three CBD-based nutraceutical products. These will target a variety of ailments, including depression, anxiety, breast cancer and fatty liver disease. In October 2017, Earth Science Tech announced a collaboration with Clinique SIDA Amité to conduct a mini-trial on its MSN-2 device for the detection of Chlamydia. ETST has also acquired Canna Inno Laboratories Inc., based in Montreal, Canada, which will give the company the opportunity to expand into Canada and gain access to local government grants for pharmaceutical industry innovation.

Earth Science Tech expects to uplist to the OTCQB Venture Exchange in early 2018, which it believes will attract well-funded institutional investors. These recent developments are likely to increase company growth and enlarge Earth Science Tech’s presence in the cannabis industry.

For more information, visit the company’s website at www.EarthScienceTech.com

More from CannabisNewsWire

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

Earth Science Tech, Inc. (ETST) Scientifically Advancing CBD

  • Company committed to scientific validation of CBD efficacy
  • Produces, markets and sells only the highest quality Full-Spectrum Hemp Oil containing CBD
  • With new subsidiaries and acquisition, future is increasingly bright

Building on vast anecdotal and mounting scientific evidence, the market for cannabidiol (CBD) products is exploding across the globe. The discovery of the human endocannabinoid system in the 1990s has intensified research and validated many of the anecdotal reports of CBD effectiveness in treating a variety of physical ailments.

Seizing on the immense market opportunity and substantiating efficacy with science, Earth Science Tech, Inc. (OTC: ETST) is focused on the science, research and studies of its high grade hemp CBD oil as a nutraceutical and dietary supplement. Earth Science already markets and sells some of the highest quality and purity Full Spectrum Hemp Oil containing CBD available. The company’s products are formulated using superior supercritical CO2 cold liquid extraction, through which the cannabinoids are kept at the rawest state possible in order to maintain essential therapeutic properties.

Earth Science believes that science is the foundation for the future of not only its high grade hemp CBD oil and its array of products, but also the entire global CBD market. In a commitment to the underlying science, Earth Science has established a research agreement with the University of Central Oklahoma and DV Biologics Laboratory to study and advance the health care benefits of its high grade hemp CBD oil. Research has already indicated that Earth Science CBD nutritional and dietary supplement products are at the top in the industrial hemp space. The company is committed to providing the public with sound scientific research and up-to-date information on the progress of studies being done on its high grade hemp CBD products.

In 2017, Earth Science launched two new subsidiaries, KannaBidioid Inc., to manufacture and distribute vapes/e-liquids and gummy edibles, and Cannabis Therapeutic Inc., to develop proprietary cannabinoid-based nutraceuticals and pharmaceutical products based on its existing CBD patent. The company also acquired Canna Inno Laboratories Inc., which will allow it access to the burgeoning Canadian market and government grants.

Earth Science’s multi-faceted, science-based approach to the development, manufacture and sale of high quality CBD products places the company in a unique and enviable position headed into 2018 and beyond. As Chief Science Officer Michel Aubé, PhD, stated in a January 3, 2018, press release (http://cnw.fm/ak2Pv), “[W]e will clearly be recognized as a leader in cannabinoids research and other health science research arena. Our future is shining bright.”

For more information, visit the company’s website at www.EarthScienceTech.com

More from CannabisNewsWire

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net